NAD+, NMN and Peptides — Why They Keep Appearing Together

First, the Straight Answer

NAD+, NMN and NR are not peptides. They contain no amino acids and no peptide bonds. They belong to a completely different chemical family — nucleotides, the same broad group that DNA and RNA are built from.

They appear alongside peptides for one reason, and it is not chemistry: they share a subject. Both turn up in research about ageing, energy and cellular decline, so shops that sell one tend to sell the other and articles about one tend to mention the other.

It is the same logic that puts running shoes and protein powder in the same shop. Nothing about a shoe resembles a scoop of powder. They sit together because the same person walks in looking for both. That is a perfectly reasonable way to organise a shop and a very poor way to understand what either thing is.

What NAD+ Actually Does

NAD+ — nicotinamide adenine dinucleotide — is a coenzyme found in every living cell. It is not a signalling molecule and not a structural one. Its job is to carry electrons during the reactions that turn food into usable energy.

Think of it as the crockery in a very busy kitchen. The plates are not the meal and nobody orders them, but every dish that leaves the pass has to travel on one. Plates get loaded, delivered, scraped and returned to be used again, thousands of times a service. NAD+ works the same way: it picks up electrons in one reaction, drops them off in another, and returns to be reloaded. It is not consumed so much as endlessly cycled.

Two things follow. First, quantity matters — a kitchen with too few plates cannot serve efficiently no matter how good the cooking is. Second, NAD+ is involved in nearly everything, because nearly every energy-producing reaction needs it. That ubiquity is what makes it interesting to ageing researchers and also what makes claims about it hard to pin down: a molecule involved in everything is difficult to credit with any one specific outcome.

NAD+ levels decline with age. That observation is well replicated and is the foundation of the entire field. What remains genuinely open is whether the decline causes age-related dysfunction, results from it, or accompanies it for other reasons — and whether raising levels back up produces meaningful benefit in humans.

Why NMN and NR Exist At All

If low NAD+ is the problem, taking NAD+ seems the obvious answer. It mostly is not, and the reason is a nice piece of cell biology.

NAD+ is a large, charged molecule and cell membranes do not readily let it through. Swallowing it largely means digesting it. So the field turned to precursors instead — smaller molecules the body can absorb and then assemble into NAD+ itself. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are the two most studied.

The distinction is delivering flat-pack furniture rather than an assembled wardrobe. The finished wardrobe will not fit through the door; the flat pack will, and the household can build it on the other side. NMN and NR are the flat pack. Which of the two gets through more efficiently, and by which route, is still argued over in the literature.

The evidence picture is worth stating plainly. Both reliably raise measurable NAD+ levels in humans — that part is well established. Whether raising NAD+ produces meaningful clinical benefit is a separate and much less settled question. Animal results have been striking; human trials have generally been small, short and focused on biomarkers rather than outcomes people would notice. This is a textbook case of the gap described in how to read peptide research: a mechanism that is well understood and an outcome that is not yet demonstrated.

Where the Two Subjects Genuinely Connect

Having separated them, it is only fair to say where the overlap is real rather than merely commercial — because there is one, and it is more interesting than the shelf-sharing.

Both are studied in mitochondria. NAD+ is central to the reactions mitochondria run, and several peptides in this library are studied for mitochondrial function from a different angle — MOTS-c is encoded in mitochondrial DNA itself, and SS-31 is studied for its interaction with the inner mitochondrial membrane. Same building, different trades: one concerns the chemistry running inside, the other the structures the chemistry runs on.

Both appear in the sirtuin literature. Sirtuins are enzymes involved in gene regulation that require NAD+ to function, which is a large part of why NAD+ attracts longevity interest. Bioregulator peptides are separately proposed to influence gene expression by a quite different route — see the bioregulator family. Two different proposed mechanisms aimed at overlapping territory.

And both fields share a weakness worth naming. Each has compelling laboratory and animal data, an intuitive mechanistic story, enthusiastic commercial promotion, and thinner human outcome evidence than the enthusiasm implies. Noticing that pattern is more useful than any individual claim from either field — it is the same shape of argument, and it should be read with the same caution in both.

This guide exists because anyone researching longevity peptides encounters NAD+, NMN and NR constantly, and deserves a clear account of what they are and are not.

Frequently Asked Questions

Published References

1. Rajman L, Chwalek K, Sinclair DA. “Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence.” Cell metabolism, 2018. PubMed
2. Martens CR, Denman BA, Mazzo MR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD(+) in healthy middle-aged and older adults.” Nature communications, 2018. PubMed
3. Covarrubias AJ, Perrone R, Grozio A, et al. “NAD(+) metabolism and its roles in cellular processes during ageing.” Nature reviews. Molecular cell biology, 2021. PubMed

Browse all NAD+, NMN and Peptides research on PubMed →